Key Points
- Edwards Lifesciences VP Daniel Lippis sold 619 shares for approximately $53,017 under a pre-arranged Rule 10b5-1 trading plan, reducing his ownership by 1.52% to 40,034 shares.
- The company’s latest quarterly results exceeded expectations, with EPS of $0.78 versus the $0.74 consensus and revenue of $1.74 billion, up 13.6% year over year. Third-quarter earnings are scheduled for November 4, 2026.
- Analyst sentiment remains broadly positive, with a “Moderate Buy” consensus and an average price target of $100.27 versus a recent share price near $84.18, although some insider selling and a recent downgrade to “Hold” may weigh on sentiment.
Edwards Lifesciences Corporation (NYSE:EW - Get Free Report) VP Daniel Lippis sold 619 shares of the business's stock in a transaction dated Thursday, October 8th. The stock was sold at an average price of $85.65, for a total transaction of $53,017.35. Following the completion of the sale, the vice president owned 40,034 shares in the company, valued at approximately $3,428,912.10. This trade represents a 1.52% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Edwards Lifesciences Stock Performance
NYSE:EW opened at $84.18 on Friday. The company has a 50-day moving average of $88.74 and a 200-day moving average of $86.17. The firm has a market cap of $48.47 billion, a price-to-earnings ratio of 48.38, a price-to-earnings-growth ratio of 2.25 and a beta of 0.87. The company has a current ratio of 4.52, a quick ratio of 3.77 and a debt-to-equity ratio of 0.06. Edwards Lifesciences Corporation has a twelve month low of $72.30 and a twelve month high of $96.29.
Edwards Lifesciences (NYSE:EW - Get Free Report) last released its earnings results on Thursday, July 23rd. The medical research company reported $0.78 EPS for the quarter, beating the consensus estimate of $0.74 by $0.04. The business had revenue of $1.74 billion during the quarter, compared to analyst estimates of $1.70 billion. Edwards Lifesciences had a net margin of 15.43% and a return on equity of 15.68%. The business's quarterly revenue was up 13.6% on a year-over-year basis. During the same period in the prior year, the business earned $0.67 earnings per share. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. Analysts forecast that Edwards Lifesciences Corporation will post 3 earnings per share for the current fiscal year.
Key Stories Impacting Edwards Lifesciences
Here are the key news stories impacting Edwards Lifesciences this week:
- Positive Sentiment: Barclays initiated coverage with an Overweight rating, also reported as a Strong-Buy recommendation. The call provides fresh bullish support for Edwards’ structural-heart-device business and could help offset recent investor caution. Barclays initiates coverage of Edwards Lifesciences with overweight rating
- Neutral Sentiment: The next major catalyst is the third-quarter earnings report. Edwards plans to release results after the market closes on November 4, 2026, followed by a conference call. Investors may remain cautious while awaiting updated procedure volumes, revenue growth and guidance. Edwards Lifesciences to Host Earnings Conference Call on November 4, 2026
- Negative Sentiment: Insider selling is adding to the pressure. Vice President Daniel Lippis sold 619 shares worth approximately $53,000 under a pre-arranged Rule 10b5-1 trading plan. Broader data cited in the report show 24 insider sales and no purchases over the past six months, which may reinforce concerns about near-term sentiment, although planned sales are not necessarily a signal of deteriorating fundamentals. Edwards Lifesciences insider transaction filing
- Negative Sentiment: Investors may be taking profits ahead of the earnings and November 2 investor event. A recent analyst shift to Hold also weighed on sentiment. However, there was no clearly negative company update; Edwards recently announced FDA approval for its AUTUS pediatric pulmonary valve.
Hedge Funds Weigh In On Edwards Lifesciences
Institutional investors and hedge funds have recently bought and sold shares of the business. BlackRock Inc. purchased a new position in Edwards Lifesciences during the second quarter valued at approximately $5,318,092,000. Bank of New York Mellon Corp purchased a new stake in Edwards Lifesciences in the 2nd quarter worth approximately $1,274,082,000. Bank of America Corp DE purchased a new stake in Edwards Lifesciences in the 2nd quarter worth approximately $605,397,000. Deutsche Bank AG acquired a new stake in shares of Edwards Lifesciences during the 2nd quarter valued at $516,552,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its stake in shares of Edwards Lifesciences by 0.6% during the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 5,488,643 shares of the medical research company's stock valued at $496,503,000 after buying an additional 30,495 shares during the period. Hedge funds and other institutional investors own 79.46% of the company's stock.
Analysts Set New Price Targets
EW has been the subject of several analyst reports. Citigroup reaffirmed a "buy" rating on shares of Edwards Lifesciences in a report on Monday. UBS Group reaffirmed a "buy" rating on shares of Edwards Lifesciences in a research note on Thursday. Wall Street Zen cut shares of Edwards Lifesciences from a "buy" rating to a "hold" rating in a report on Saturday, September 26th. BTIG Research restated a "buy" rating and set a $110.00 price target on shares of Edwards Lifesciences in a report on Friday, September 11th. Finally, Evercore reaffirmed an "outperform" rating and issued a $100.00 price objective on shares of Edwards Lifesciences in a research note on Monday, July 6th. One analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and five have assigned a Hold rating to the company's stock. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $100.27.
Check Out Our Latest Report on Edwards Lifesciences
Edwards Lifesciences Company Profile
(
Get Free Report)
Edwards Lifesciences Corporation is a medical technology company focused on therapies for structural heart disease and other cardiovascular conditions. The company develops and manufactures heart valve replacement and repair technologies, including transcatheter aortic valve replacement systems, surgical heart valves, transcatheter mitral and tricuspid therapies, and related delivery systems and accessories.
Founded in 1958 by engineer Miles “Lowell” Edwards, the company helped pioneer artificial heart valves and has played a significant role in the development of transcatheter valve replacement.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
